Search Videos and More

Showing 1 - 6 of 6 results

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG) News

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART) News

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
Dose-Attenuated Chemotherapy in Patients with Lung Cancer and Age >/= 70 and/or Comorbidities News

Dose-Attenuated Chemotherapy in Patients with Lung Cancer and Age >/= 70 and/or Comorbidities

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study News

Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study

This phase II trial tests the effect of hemp-based cannabidiol (CBD) in preventing oxaliplatin (Ox)-induced peripheral neuropathy (OIPN) in patients with colorectal cancer (CRC) that has spread to nearby tissue or lymph nodes and cannot be removed by surgery (locally advanced unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic).
Pembrolizumab Maintenance After Enfortumab Vedotin/Pembrolizumab Induction in Frontline Metastatic Urothelial Carcinoma (IMPROEV) News

Pembrolizumab Maintenance After Enfortumab Vedotin/Pembrolizumab Induction in Frontline Metastatic Urothelial Carcinoma (IMPROEV)

This is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve patients with metastatic urothelial carcinoma (mUC).
Scrambler Therapy with Duloxetine-Based Usual Care vs. Duloxetine-Based Usual Care for Chemotherapy-Induced Peripheral Neuropathy News

Scrambler Therapy with Duloxetine-Based Usual Care vs. Duloxetine-Based Usual Care for Chemotherapy-Induced Peripheral Neuropathy

The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form.